| Budget Amount *help |
¥44,850,000 (Direct Cost: ¥34,500,000、Indirect Cost: ¥10,350,000)
Fiscal Year 2014: ¥14,560,000 (Direct Cost: ¥11,200,000、Indirect Cost: ¥3,360,000)
Fiscal Year 2013: ¥14,300,000 (Direct Cost: ¥11,000,000、Indirect Cost: ¥3,300,000)
Fiscal Year 2012: ¥15,990,000 (Direct Cost: ¥12,300,000、Indirect Cost: ¥3,690,000)
|
|---|
| Outline of Final Research Achievements |
Transplantation of islets has been carried out to treat insulin-dependent diabetes mellitus. However, islet grafts must be maintained by administration of immunosuppressive drugs, which can lead to complications in the long term. An approach that enables to avoid immunosuppressive drug use is desirable. In this study, we examined the transplantation of co-aggregates of islet cells and other types of cells which have immune suppressive functions, such as regulatory T cells and Sertoli cells and mesenchymal stem cells (MSC). After intraportal transplantation of the co-aggregates into chemically induced diabetic mice, Treg cells or Sertoli cells in the aggregates enabled the long-term survival of allogeneic islet cell grafts in the liver without any use of immunosuppressive drugs. Functional evaluation of MSC-islet co-aggregates confirmed normal insulin secretory function and partial suppression of anti-CD3-activated splenocyte proliferation.
|
